Everest Medicines Ties With Tencent to Scale Last Mile to Patient Care

Back-to-back deals with Tencent and Medbanks Health seek to build new distributing partnerships ahead of expected first drug approvals Key points: Everest Medicines could gain valuable distribution channels through its new partnerships with Tencent and Medbanks Both new partners have users bases on ‘closed-loop’ healthcare platforms providing everything from checkups to drug sales By Richard Barbarossa What do cutting-edge cancer drugs and social media have in common? Not much, really. But that unlikely pairing is bringing together cancer and autoimmune disorder drug startup Everest Medicines Ltd. (1952.HK) and leading social…

Read MORE »

Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock

Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled over the past six months on major licensing deal, fundraising and pending drug approvals Appointment of two new well-connected board members could expedite first approvals of company’s drugs in China By Richard Barbarossa Cancer drug developer I-Mab (IMAB.US) has been on a roll this year. The company’s shares have nearly doubled in the past six months after it recorded its…

Read MORE »

Pharmaron, I-Mab and Burning Rock Get Investor Validation From MSCI

Three up-and-coming Chinese pharma companies are among those included in latest adjustment for the index compiler’s China All Shares Index Key takeaways: MSCI’s addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential Inclusion typically represents validation for a company’s products and outlook By Richard Barbarossa Drug and healthcare R&D firms are well-represented in the latest round of additions to the MSCI China All Shares Index, highlighting the sector’s growth potential and strong fundamentals. Some new ascendants to the list are even…

Read MORE »

Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology

Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China  Key Takeaways: New China licensing deals and oncology focus come amid earnings slump, though profit declines eased in second half of 2020 Despite securing big name cornerstone investors, company’s shares have tumbled 40% since its October Hong Kong IPO, following its New York de-listing six years earlier By Richard Barbarossa Generic drug maker Simcere Pharmaceutical Group Ltd. (2906.HK) has sold off a money-losing unit making cell therapy drugs and is placing…

Read MORE »

Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own

Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology and immunology business will more than triple on new approvals and more direct control over its sales and marketing Stiff competition in cancer drugs and divestiture of its profitable but non-core OTC business could result in continued net losses By Richard Barbarossa Hutchison China MediTech Ltd. (Nasdaq: HCM; HCM.L), a leading Chinese maker of cancer drugs backed by Hong Kong…

Read MORE »

Biosimilar Specialist Henlius Takes Off. Now Comes the Hard Part

Fosun Pharma-backed company posts huge revenue jump in the second half of last year, as it boosts production and signs more global licensing deals to stay ahead of competition Key takeaways: Henlius is one of the earliest entrants to China’s young biosimilar market, giving it a first-mover advantage The company will need to quickly develop more new drugs, boost production and sign new partnerships to stay ahead in an increasingly crowded field By Richard Barbarossa Biosimilar specialist Shanghai Henlius Biotech, Inc. (HKEx: 2696) is set to ramp up production after…

Read MORE »